APLS vs. MRNA, VTRS, GMAB, SMMT, RDY, SRPT, CTLT, QGEN, PCVX, and ITCI
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Qiagen (QGEN), Vaxcyte (PCVX), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs.
Apellis Pharmaceuticals (NASDAQ:APLS) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
Apellis Pharmaceuticals has a net margin of -34.97% compared to Moderna's net margin of -43.77%. Moderna's return on equity of -17.68% beat Apellis Pharmaceuticals' return on equity.
In the previous week, Apellis Pharmaceuticals and Apellis Pharmaceuticals both had 8 articles in the media. Apellis Pharmaceuticals' average media sentiment score of 1.55 beat Moderna's score of 0.05 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.
Apellis Pharmaceuticals received 131 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.39% of users gave Apellis Pharmaceuticals an outperform vote while only 55.21% of users gave Moderna an outperform vote.
Apellis Pharmaceuticals has higher earnings, but lower revenue than Moderna. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 15.7% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Apellis Pharmaceuticals presently has a consensus target price of $49.94, indicating a potential upside of 49.27%. Moderna has a consensus target price of $79.50, indicating a potential upside of 88.48%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than Apellis Pharmaceuticals.
Apellis Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.
Summary
Apellis Pharmaceuticals beats Moderna on 11 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 1/6/2025 by MarketBeat.com Staff
Free APLS Stock Alerts